PRODUCT DEVELOPMENT PIPELINE.

At Notch, we are leveraging our core technologies and capabilities to build a robust pipeline of next-generation cellular immunotherapies designed to offer transformational benefits over the existing standard of care.

Our initial focus is on the development of iPSC-derived T cells for treating hematological malignancies, in partnership with Allogene Therapeutics. In addition, we are advancing the development of wholly owned immune cell therapies for solid tumor indications.

---